Innovation in delivering synthetically challenging bicyclic arginase inhibitors to enhance immunotherapy
- Derun Lia, Hongjun Zhanga, Thomas W. Lyonsa, Theodore A. Martinota, Abdelghani Achaba, Min lua, Lisa M. Noglea, Spencer McMinna, Matthew J. Mitcheltreea, Matthew Childersa, Qinglin Pua, Symon Gathiakaa, Anand Palania, Kalyan Chakravarthya, Amy D. DeCastroa, Jennifer O'Neila, Roshi Afshara, Nicole C. Walsha, Peter W. Fana, Mangeng Chenga, Richard Millera, Amy Dotya, Rachel Paltea, Hai-Young Kima, Josep Sauría, Adam Bearda, Christopher Brynczkaa and Christian Fischera
- aMerck Research Laboratory, Boston, MA.Read the publication that featured this abstract
Arginase overexpression has been associated with poor survival rates in advanced cancer patients treated with Keytruda. High levels of Arginase may lead to a depletion of arginine within the tumor microenvironment, inhibiting the immune response. Thus, arginase inhibition has the potential to greatly enhance immunotherapy treatment. Discovering novel arginase inhibitors was met with several challenges including analyzing/purifying extremely polar chemical matter without chromophores, synthetically challenging space, and poor bioavailability of compounds with ClogP less than minus two.
Cross-functional collaborations and innovations rapidly overcame these challenges. Structural chemistry and modeling guided the design of novel arginase inhibitors. Analytical and purification groups developed innovative analytical/purification methods. Novel technologies including ReatIR and Vapourtec flow system, provided key intermediates to enable chartering into synthetically challenging space. Through creative cyclization strategies and active transport strategy to improve bioavailability, the team ultimately delivered a diverse set of potent and extremely synthetically challenging arginase inhibitors to study the potential of arginase inhibition. Preliminary in vivo evaluation showed single agent efficacy in an EMT6 model. These arginase inhibitors have the potential to enhance immunotherapy.
Get in touch
For more information on flow chemistry systems and services please use the contact methods below.
Call us on +44 (0)1284 728659 or Email us
The Vapourtec R-Series is, quite simply, unrivalled for flow chemistry
- Flexible |
- Precise |
The R-Series is undoubtedly the most versatile, modular flow chemistry system available today.
The Vapourtec E-Series is the perfect introductory system for flow chemistry
- Robust |
- Easy to use |
The E-Series is a robust and affordable, entry level flow chemistry system designed for reliability and ease of use.